SCHEMBL5228488

SCHEMBL5228488

COc1cc(S(=O)(=O)N2CCOCC2)ccc1-c1nc2c(c(-c3ccccc3)nn2C)c(=O)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
MAPK1 P28482 1/20 0.47
RECQL P46063 1/20 0.47
KMT2A Q03164 1/20 0.47
PDE5A O76074 4/20 0.46
ALDH1A1 P00352 5/20 0.44
PDE7A Q13946 1/20 0.44
GAA P10253 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE1C Q14123 1/20 0.41
CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5231363 0.92 PDE5A (0.55) MAPTPDE5APDE7AGAASMN1; SMN2
SCHEMBL5232179 0.91 PDE5A (0.46) MAPTMEN1KMT2APDE5APDE7A
SCHEMBL5232114 0.90 PDE5A (0.46) MAPTMEN1MAPK1RECQLKMT2A
SCHEMBL5232459 0.90 PDE5A (0.43) MAPTMEN1MAPK1RECQLKMT2A
SCHEMBL5232735 0.89 PDE5A (0.48) MAPTPDE5APDE7AGAASMN1; SMN2
SCHEMBL5230435 0.89 PDE7A (0.46) MAPTMEN1KMT2APDE5APDE7A
SCHEMBL5235418 0.89 PDE7A (0.48) MAPTMEN1KMT2APDE5APDE7A
SCHEMBL5230317 0.88 PDE7A (0.47) MAPTMEN1KMT2APDE5APDE7A
SCHEMBL5235267 0.88 APEX1 (0.47) MAPTMEN1MAPK1KMT2APDE5A
SCHEMBL5231579 0.86 PDE7A (0.45) MAPTPDE5APDE7AGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A MAPT 4356/4885MEN1 4100/4885MAPK1 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.